TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34390869
Drug: AAV8-RS1 gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: AAV8-RS1 gene replacement therapy administered intravitreally in a phase I/IIa trial
Study: 34390869
Drug: AAV8-RS1 gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: AAV8-RS1 gene replacement therapy
Study: 34391393
Drug: Cannabidiol 600
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol 600 mg (300 mg BID)
Study: 34391393
Drug: Risperidone 4
Normalized name: risperidone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 4 mg (2 mg BID)
Study: 34391480
Drug: BI 187004
Normalized name: BI-187004
DrugBank: BI-187004 (DB18897)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 187004 (2.5-360 mg)
Study: 34391480
Drug: BI 187004
Normalized name: BI-187004
DrugBank: BI-187004 (DB18897)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 187004 (5 mg)
Study: 34391480
Drug: BI 187004
Normalized name: BI-187004
DrugBank: BI-187004 (DB18897)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 187004 (160 mg)
Study: 34391480
Drug: BI 187004
Normalized name: BI-187004
DrugBank: BI-187004 (DB18897)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 187004 (10 mg)
Study: 34391480
Drug: BI 187004
Normalized name: BI-187004
DrugBank: BI-187004 (DB18897)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 187004 (360 mg)
Study: 34391791
Drug: Single high-sensitive
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high-sensitive cardiac troponin I (hs-cTnI) measurement at admission, diagnostic cut-off <3 ng/L
Study: 34391922
Drug: AFP (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: AFP (20 ng/mL or greater)
Study: 34392453
Drug: GT0918 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: GT0918 (500 mg QD)
Study: 34393800
Drug: Corticosteroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid treatment (doses not specified)
Study: 34394782
Drug: Tiotropium/olodaterol 5/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium/olodaterol 5/5 µg fixed dose combination for 6 weeks
Study: 34394782
Drug: Tiotropium/olodaterol treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium/olodaterol treatment
Study: 34395277
Drug: Preoperative systemic
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative systemic treatment
Study: 34395560
Drug: Subcutaneous Implantable
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Implantable Cardioverter-Defibrillator (S-ICD) implantation
Study: 34396157
Drug: Trastuzumab with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab with ACE inhibitors and/or beta-blockers
Study: 34396210
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist degarelix
Study: 34396210
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist leuprolide
Study: 34397042
Drug: Consecutive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consecutive therapy consisting of esomeprazole 40 mg or rabeprazole 20 mg twice daily, amoxicillin 1,000 mg twice daily, tetracycline 500 mg 4 times daily, and furazolidone 100 mg 3 times daily for the first 7 days, followed by colloidal bismuth pectin 200 mg twice daily for another 7 days.
Study: 34397042
Drug: Consecutive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consecutive therapy including amoxicillin, tetracycline, and furazolidone.
Study: 34397042
Drug: Resistance rates
Normalized name: Quarter Mate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance rates to antibiotics in patients with available antimicrobial susceptibility testing results (51 patients).
Study: 34397539
Drug: Symptomatic management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic management and traditional therapies for congestive heart failure
Study: 34397707
Drug: Control of
Normalized name: A replication-competent adenovirus type 5 in which the E1A and E1B genes are under the control of a human telomerase reverse transcriptase (hTERT) and IRES, respectively.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control of low-density lipoprotein cholesterol (LDL-C) < 2.6 mmol/l
Study: 34397719
Drug: Triptorelin (Diphereline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin (Diphereline, 3.75 mg intramuscular injection once every 28 days for up to 24 weeks) - Group A (1-3 injections)
Study: 34397719
Drug: Triptorelin (Diphereline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin (Diphereline, 3.75 mg intramuscular injection once every 28 days for up to 24 weeks) - Group B (4-6 injections)
Study: 34397987
Drug: empagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: empagliflozin (10 mg once daily)
Study: 34397987
Drug: sitagliptin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: sitagliptin (100 mg once daily)
Study: 34398238
Drug: Interleukin-7 (IL-7)
Normalized name: interleukin-7
DrugBank: Interleukin-7 (DB11997)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-7 (IL-7) administration to ICL patients
Study: 34398588
Drug: Surgically Targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgically Targeted Radiation Therapy (STaRT) with GammaTile
Study: 34398971
Drug: Chidamide-cladribine-gemcitabine-busulfan (ChiCGB)
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chidamide-cladribine-gemcitabine-busulfan (ChiCGB) combination as conditioning therapy after transplantation with autologous peripheral stem cells.
Study: 34398971
Drug: Chidamide-cladribine-gemcitabine-busulfan (ChiCGB)
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chidamide-cladribine-gemcitabine-busulfan (ChiCGB) combination as conditioning therapy.
Study: 34399737
Drug: Dignity Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dignity Therapy (DT) intervention
Study: 34399811
Drug: Headache and
Normalized name: Flonase Headache and Allergy Relief
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Headache and nausea/vomiting combination
Study: 34400137
Drug: Hysterectomy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hysterectomy and lymph node staging without adjuvant therapy
Study: 34400337
Drug: Control groups
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control groups (HDS containing green tea without G cambogia and other HDS)
Study: 34401374
Drug: Online cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online cognitive behavior therapy (CBT) targeting avoidance behavior, duration: 8 weeks, with therapist support
Study: 34401600
Drug: BLZ-100 (tozuleristide)
Normalized name: BLZ-945
DrugBank: BLZ-945 (DB16838)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BLZ-100 (tozuleristide) administered intravenously at doses of 1, 3, 6, 12, and 18 mg, 2 days before tumor excision.
Study: 34401600
Drug: BLZ-100 (tozuleristide)
Normalized name: BLZ-945
DrugBank: BLZ-945 (DB16838)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BLZ-100 (tozuleristide) administered intravenously at intermediate doses (3-12 mg).
Study: 34401600
Drug: BLZ-100 (tozuleristide)
Normalized name: BLZ-945
DrugBank: BLZ-945 (DB16838)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BLZ-100 (tozuleristide) administered intravenously.
Study: 34401861
Drug: Atorvastatin-based lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin-based lipid therapies and lifestyle intervention for 2 years
Study: 34403125
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for chronic pain and shared decision-making for prescription opioid dose reduction
Study: 34404358
Drug: Curcumin 1500
Normalized name: Nature's Truth Turmeric Curcumin 1500 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin 1500 mg by mouth twice daily for 12 weeks
Study: 34404463
Drug: Secukinumab 300
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 300 mg subcutaneously at baseline, weeks 1, 2, and 3, and every 4 weeks from week 4, combined with a 26-week prednisolone taper regimen.
Study: 34404463
Drug: Placebo subcutaneously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneously at baseline, weeks 1, 2, and 3, and every 4 weeks from week 4, combined with a 26-week prednisolone taper regimen.
Study: 34404711
Drug: Acute kidney
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute kidney replacement therapy (KRT)
Study: 34404711
Drug: Driving safety,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Driving safety, adverse events, and medication adherence assessment
Study: 34405140
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of CD45RA memory T cells
Study: 34405577
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiation therapy (SBRT) at doses of 35 Gy, 37.5 Gy, 40 Gy, 42.5 Gy, and 45 Gy in five fractions
Study: 34406502
Drug: Topical low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical low-dose (1,005 mg) preservative-free hydrocortisone, administered twice daily in each eye for 2 weeks.
Study: 34407260
Drug: 4 mm
Normalized name: potassium 8.4 MMOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mm pen needles combined with education on injection technique
Study: 34407735
Drug: Inotuzumab ozogamicin
Normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inotuzumab ozogamicin in combination with temsirolimus
Study: 34407844
Drug: M2698 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: M2698 monotherapy (15-380 mg daily)
Study: 34407844
Drug: M2698/trastuzumab (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: M2698/trastuzumab (160 mg QD)
Study: 34407844
Drug: M2698/tamoxifen (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: M2698/tamoxifen (160 mg QD/240 mg intermittent regimen)
Study: 34407972
Drug: MTL-CEBPA combined
Normalized name: Allium cepa bulb extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTL-CEBPA combined with checkpoint inhibitors or PMN-MDSC-targeted immunotherapy
Study: 34408049
Drug: Tenofovir alafenamide
Normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tenofovir alafenamide fumarate (TAF) monotherapy
Study: 34408750
Drug: 6B11-OCIK adoptive
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6B11-OCIK adoptive cell therapy (autologous T cells induced by 6B11 minibody plus dendritic cells and cytokines)
Study: 34409288
Drug: 1MIU low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1MIU low-dose interleukin-2
Study: 34409288
Drug: 2MIU low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2MIU low-dose interleukin-2
Study: 34409593
Drug: ACEI or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI or ARBs treatment
Study: 34409593
Drug: No ACEI
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ACEI or ARBs treatment
Study: 34409593
Drug: ACEI or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI or ARBs treatment at discharge
Study: 34409593
Drug: Antiviral drugs,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral drugs, interferon treatment, oral anticoagulation at discharge
Study: 34411009
Drug: Intranasal esketamine
Normalized name: esketamine
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intranasal esketamine
Study: 34411009
Drug: Intravenous racemic
Normalized name: EPINEPHRINE,RACEMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous racemic ketamine
Study: 34412682
Drug: Camostat tablets,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camostat tablets, 200 mg four times daily (qds) for 14 days
Study: 34412687
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol for 6 months
Study: 34413106
Drug: Web-based self-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based self-administered health-related data collection system
Study: 34413166
Drug: Cemiplimab 3
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cemiplimab 3 mg/kg every 2 weeks (group 1, mCSCC)
Study: 34413166
Drug: Cemiplimab 3
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cemiplimab 3 mg/kg every 2 weeks (group 2, locally advanced CSCC)
Study: 34413166
Drug: Cemiplimab 350
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cemiplimab 350 mg every 3 weeks (group 3, mCSCC)
Study: 34413210
Drug: High-dose inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose inhaled nitric oxide (INO) at 160 ppm for 15 min twice daily
Study: 34413210
Drug: Electric NO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electric NO (eNO) generator at 160 ppm for 15 min twice daily
Study: 34413210
Drug: Pressurized nitrogen/NO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressurized nitrogen/NO cylinders (INO) at 160 ppm for 15 min twice daily
Study: 34413249
Drug: Respiratory treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Respiratory treatment
Study: 34413249
Drug: Factors associated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Factors associated with respiratory treatment
Study: 34414532
Drug: Ribociclib 600
Normalized name: letrozole 2.5 MG / ribociclib 600 MG Daily Dose Carton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib 600 mg/day (3-weeks-on/1-week-off) plus letrozole 2.5 mg/day and monthly goserelin/leuprolide in men and pre-/perimenopausal women
Study: 34414986
Drug: Immunological studies
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immunological studies (in vitro stimulation with toll-like receptor ligands)
Study: 34415049
Drug: Seasonal influenza
Normalized name: seasonal influenza, intradermal, preservative free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seasonal influenza vaccination (2 doses for HSCT patients)
Study: 34415114
Drug: MINT therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MINT therapy (wearable myoelectric interface)
Study: 34415964
Drug: Cohort 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1 (received standard dose)
Study: 34415964
Drug: Cohort 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 2 (received higher first dose and fractional fifth dose)
Study: 34415964
Drug: Cohort 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 2 (fractional fifth dose)
Study: 34416160
Drug: Antiangiogenic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiangiogenic agents combined with systemic chemotherapy
Study: 34416167
Drug: PD-1/L1 therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1/L1 therapy followed by MAPK inhibitors (MAPKi)
Study: 34416167
Drug: MAPK inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAPK inhibitors (MAPKi)
Study: 34416175
Drug: Oral tenofovir
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral tenofovir disoproxil fumarate (300 mg/day) initiated between 28-32 weeks of gestation and continued through 12 weeks postpartum.
Study: 34416175
Drug: Birth-dose of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Birth-dose of monovalent HBV vaccine (Euvax-B Pediatric: 0.5 mL) administered within 24 hours of life.
Study: 34416175
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment or vaccination (control group not explicitly mentioned).
Study: 34416758
Drug: Pharmacotherapy (specifics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy (specifics not provided)
Study: 34417144
Drug: Trametinib 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trametinib 1.5 mg oral daily and panitumumab 4.8 mg/kg IV every 2 weeks
Study: 34417162
Drug: PNT2258 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: PNT2258 120 mg/m intravenously
Study: 34417212
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of GST-π and PRDX1
Study: 34417444
Drug: Obinutuzumab-atezolizumab-lenalidomide (G-atezo-len)
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab-atezolizumab-lenalidomide (G-atezo-len)
Study: 34417675
Drug: Veliparib 30
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib 30 to 40 mg twice daily on days 1 to 7 with concurrent temozolomide 150 mg/m²
Study: 34417919
Drug: Lactate concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate concentration ≥ 2.0 mmol/L on the day of ICU admission (baseline)
Study: 34418086
Drug: Diazepam nasal
Normalized name: diazepam Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam nasal spray (Valtoco) administered 4390 times for 3853 seizure clusters
Study: 34418086
Drug: Diazepam nasal
Normalized name: diazepam Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam nasal spray (Valtoco)
Study: 34419010
Drug: Enhanced usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced usual care (EUC) including depression treatment according to clinical guidelines and usual medical care for chronic diseases
Study: 34419752
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT) for depression; 20 individual sessions over 16 weeks
Study: 34420548
Drug: 4000 L
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4000 L production-scale alglucosidase alfa
Study: 34421148
Drug: Subanesthetic intravenous
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subanesthetic intravenous ketamine
Study: 34421925
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone pulse therapy (IVMP) alone
Study: 34421925
Drug: IVMP combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVMP combined with intravenous immunoglobulin
Study: 34423319
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy for ARFID (CBT-AR), 20-30 outpatient sessions delivered by therapists.
Study: 34424319
Drug: LCL161 (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCL161 (oral, starting dose, 1500 mg per week)
Study: 34424546
Drug: Standard-dose rhGH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose rhGH (approximately 0.3 mg/kg/week)
Study: 34424546
Drug: High-dose rhGH
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rhGH (0.5 mg/kg/week)
Study: 34424934
Drug: Supplement (2g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement (2g fish oil with 1500 IU vitamin D3 1x/d + 20-30g whey protein powder with 3g leucine 2x/d)
Study: 34425261
Drug: High-dose post-transplantation
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose post-transplantation cyclophosphamide (PTCy)
Study: 34425406
Drug: Palbociclib plus
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib plus endocrine therapy (exemestane or fulvestrant)
Study: 34425763
Drug: Interferon beta-1b
Normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1b (IFNB-1b) treatment started within 6 months before study entry.
Study: 34425825
Drug: Self-reported oral
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported oral health
Study: 34425825
Drug: Children's oral
Normalized name: Maalox Children's Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children's oral health related quality of life
Study: 34425850
Drug: YY-20394 (20-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: YY-20394 (20-200 mg daily)
Study: 34425850
Drug: YY-20394 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: YY-20394 (40 mg q.d.)
Study: 34425850
Drug: YY-20394 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: YY-20394 (80 mg q.d.)
Study: 34426012
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitors (ACEis) or angiotensin receptor blockers (ARBs)
Study: 34426012
Drug: Glucagon-like peptide
Normalized name: Glucagon-like peptide 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon-like peptide 1 receptor agonists (GLP-1RAs)
Study: 35441935
Drug: Steroidal mineralocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroidal mineralocorticoid receptor antagonists (MRAs)
Study: 34426402
Drug: Subconjunctival dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subconjunctival dexamethasone implant injected at the end of PK
Study: 34426402
Drug: Subconjunctival dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subconjunctival dexamethasone implant
Study: 34426402
Drug: Steroid eye-drop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid eye-drop treatment planned after implant resorption
Study: 34426443
Drug: Telisotuzumab vedotin
Normalized name: Telisotuzumab vedotin
DrugBank: Telisotuzumab vedotin (DB15104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telisotuzumab vedotin (Teliso-V) monotherapy at a dose of 1.9 mg/kg once every 2 weeks
Study: 34426443
Drug: Telisotuzumab vedotin
Normalized name: Telisotuzumab vedotin
DrugBank: Telisotuzumab vedotin (DB15104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telisotuzumab vedotin (Teliso-V) monotherapy at a dose of 2.7 mg/kg once every 3 weeks
Study: 34427465
Drug: Standard NAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard NAC with or without experimental agents